.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF02_Pembrolizumab.Pembrolizumab

Information

Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1, a receptor on T cells, and its ligands, PD-L1 and PD-L2, thereby promoting immune-mediated anti-tumor activity. It is primarily used in the treatment of various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and others. Pembrolizumab is FDA-approved for multiple cancer indications and is in active clinical use.

Pharmacokinetics

Pharmacokinetic parameters reported for adult cancer patients (both sexes, broad adult age range) receiving intravenous pembrolizumab monotherapy.

References

1. Freshwater, T, et al., & Stone, JA (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for immunotherapy of cancer 5 43–None. DOI:10.1186/s40425-017-0242-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28515943

2. Lala, M, et al., & Jain, L (2020). A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. European journal of cancer (Oxford, England : 1990) 131 68–75. DOI:10.1016/j.ejca.2020.02.016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32305010

3. Baranda, JC, et al., & Hodi, FS (2024). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17(6) e13854–None. DOI:10.1111/cts.13854 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38898592

Revisions

• 06/2025 initial generated model